Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials. Issue 4 (8th April 2021)

• Record Type: Journal Article
• Authors: Wei, Ling; Zhang, Weizhi; Yang, Yifeng; Li, Dongping
• Is Part Of: BMJ open. Volume 11:Issue 4(2021)
• Publication Date: 2021-04-08
• Subjects: radiation biology -- interventional radiology -- acute renal failure -- coronary intervention; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-043436
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To summarise current evidence on the use of pentoxifylline (PTX) to prevent contrast-induced nephropathy (CIN). Methods: The PubMed, Embase and CENTRAL databases were searched for randomised controlled trials including patients with and without PTX undergoing contrast media exposure. We analysed the incidence of CIN and serum creatinine changes before and after contrast media exposure. All statistical analyses were conducted with Review Manager V.5.3. Results: We finally enrolled in seven randomised controlled trials with a total of 1484 patients in this analysis. All of seven included studies were performed in patients undergoing angioplasty or stenting. The overall rates of CIN were 8.8% and 10.4% in the PTX groups and control groups, respectively. However, no significant reduction in the CIN rate was observed in the patients treated with PTX compared with the control groups (OR 0.81, 95% CI 0.57 to 1.13, I 2 =0, p=0.21). All studies reported no hospital mortality and the new requirement for dialysis during the trials. Conclusion: Perioperative administration of PTX to patients undergoing angioplasty did not significantly reduce the development of CIN but showed some weak tendency of lower serum creatinine increase. Based on the available trials, the evidence does not support the administration of PTX for the prevention of CIN. More trials with larger sample sizes are needed to evaluate the role of PTX in CIN prevention.